Strategic collaboration Systasy is actively partnering with academic and industry players on neutrophil-derived inflammatory diseases, presenting a sales opportunity to offer their AI-supported barcoding platform and biomarker discovery capabilities to research collaborations and joint development programs with pharmaceutical and university partners.

Therapy focus The company is developing novel therapies for neutrophil-derived inflammatory diseases, signaling a potential for CRO or biotech service collaborations, data analytics support, and access to their patient-derived models and pathway screens to de-risk early-stage programs.

Data and AI edge Their AI-supported platform for patient stratification and biomarker discovery, plus hyper-multiplexed pathway screens, offers an opening to provide complementary data services, analytics tooling, or consulting to optimize target identification and clinical trial design.

Barcoding capability Proprietary DNA barcoding and biodistribution analysis across viral serotypes presents a compelling case for partnering on vector research, translational studies, and potential contract work for academic labs or biotech developers seeking precision profiling.

Growth signals With revenue in the low-to-mid millions and a lean team, Systasy may be exploring scalable partnerships, licensing opportunities, or service-led engagements to accelerate go-to-market plans, making it suitable for scalable service packages or technology licensing discussions.